Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTH Cyclo Therapeutics	$0.72	$0.72	$0.55 ▼ $1.45	$23.72M	-0.57	538,098 shs	N/A
FBLG FibroBiologics	$0.62 -1.2%	$0.88	$0.60 ▼ $5.62	$23.45M	-0.79	300,003 shs	437,714 shs
IXHL Incannex Healthcare	$0.21 -1.7%	$0.24	$0.08 ▼ $3.12	$6.24M	7.64	14.54 million shs	11.56 million shs
KLTO Klotho Neurosciences	$1.10 -2.7%	$0.60	$0.11 ▼ $3.91	$35.71M	0.18	21.26 million shs	7.53 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTH Cyclo Therapeutics	0.00%	0.00%	0.00%	0.00%	-43.26%
FBLG FibroBiologics	+0.66%	-13.69%	-12.99%	-27.65%	-87.53%
IXHL Incannex Healthcare	+6.10%	+7.85%	+6.68%	-68.28%	-92.66%
KLTO Klotho Neurosciences	+56.92%	-5.83%	+511.80%	+393.45%	+112,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	2.9561 of 5 stars	3.6	2.0	0.0	0.0	2.2	3.3	0.6
IXHL Incannex Healthcare	0.7224 of 5 stars	0.0	4.0	0.0	0.0	2.7	0.8	0.0
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTH Cyclo Therapeutics	2.33	Hold	$0.95	31.83% Upside
FBLG FibroBiologics	3.20	Buy	$13.00	2,013.82% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IXHL, CYTH, FBLG, and KLTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTH Cyclo Therapeutics	$870.73K	27.24	N/A	N/A	$0.21 per share	3.43
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.08 per share	N/A
IXHL Incannex Healthcare	$10K	623.92	N/A	N/A	$0.18 per share	1.18
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTH Cyclo Therapeutics	-$20.06M	-$0.90	N/A	N/A	N/A	-2,847.19%	N/A	-307.16%	N/A
FBLG FibroBiologics	-$11.16M	-$0.21	N/A	N/A	N/A	N/A	-1,022.04%	-117.56%	8/6/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	N/A
KLTO Klotho Neurosciences	-$6.15M	-$0.36	N/A	∞	N/A	N/A	-1,779.01%	-275.01%	N/A

Latest IXHL, CYTH, FBLG, and KLTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/15/2025	Q1 2025	KLTO Klotho Neurosciences	N/A	-$0.08	N/A	-$0.08	N/A	N/A
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTH Cyclo Therapeutics	N/A	0.17	0.16
FBLG FibroBiologics	N/A	1.14	1.14
IXHL Incannex Healthcare	N/A	2.12	2.12
KLTO Klotho Neurosciences	N/A	0.29	0.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTH Cyclo Therapeutics	68.55%
FBLG FibroBiologics	N/A
IXHL Incannex Healthcare	0.43%
KLTO Klotho Neurosciences	20.07%

Insider Ownership

Company	Insider Ownership
CYTH Cyclo Therapeutics	29.78%
FBLG FibroBiologics	20.80%
IXHL Incannex Healthcare	15.49%
KLTO Klotho Neurosciences	26.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTH Cyclo Therapeutics	9	32.92 million	23.12 million	No Data
FBLG FibroBiologics	10	38.26 million	30.30 million	N/A
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
KLTO Klotho Neurosciences	N/A	32.49 million	23.82 million	N/A

IXHL, CYTH, FBLG, and KLTO Headlines

Recent News About These Companies

Klotho Neurosciences moves forward with manufacturing gene therapy to treat amyotrophic lateral sclerosis

July 1 at 6:54 AM | pharmabiz.comP

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

June 30 at 2:00 AM | prnewswire.com

Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population

June 24, 2025 | prnewswire.com

Contrasting Klotho Neurosciences (KLTO) and Its Rivals

June 21, 2025 | americanbankingnews.com

KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS

June 18, 2025 | prnewswire.com

KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

June 16, 2025 | prnewswire.com

Best Penny Stocks To Research - June 10th

June 10, 2025 | marketbeat.com

Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?

June 10, 2025 | forbes.com

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon

June 10, 2025 | msn.com

Penny Stocks To Watch Today - June 9th

June 9, 2025 | marketbeat.com

Promising Small Cap Stocks Worth Watching - June 9th

June 9, 2025 | marketbeat.com

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")

June 9, 2025 | prnewswire.com

Nasdaq Top 5 Premarket Losers: Healthcare Triangle, Klotho Neurosciences, New Fortress Energy, NanoVibronix, MDJM

May 15, 2025 | msn.com

Protein discovered that boosts lifespan, muscle, and brain power with just one dose

May 10, 2025 | earth.comE

Klotho: A protein that promotes healthy aging and improves longevity

May 9, 2025 | msn.com

Boosting Klotho Protein Slows Aging and Enhances Health

May 9, 2025 | neurosciencenews.comN

Klotho Neurosciences faces Nasdaq delisting risk

April 23, 2025 | investing.com

Klotho Neurosciences to Acquire SkyBell Tech Subsidiary

April 3, 2025 | investing.com

Klotho Neurosciences, Inc. (KLTO)

February 2, 2025 | ca.finance.yahoo.com

Klotho Neuroscience Inc (KLTO)

January 28, 2025 | investing.com

Klotho Neurosciences secures $2M in convertible notes and warrants

January 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, CYTH, FBLG, and KLTO Company Descriptions

Cyclo Therapeutics NASDAQ:CYTH

$0.72 0.00 (0.00%)

As of 03/26/2025

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

FibroBiologics NASDAQ:FBLG

$0.62 -0.01 (-1.16%)

As of 03:19 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Incannex Healthcare NASDAQ:IXHL

$0.21 0.00 (-1.72%)

As of 03:19 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Klotho Neurosciences NASDAQ:KLTO

$1.10 -0.03 (-2.73%)

As of 03:04 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time